Predicting migraine responsiveness to botulinum toxin type A injections

Archives of Dermatology

Volumn 146, Issue 2, 2010, Pages 159-163

  Kim, Christine C ^a,e   Bogart, Megan M ^a,e   Wee, Sue Ann ^a,e   Burstein, Rami ^b   Arndt, Kenneth A ^a,c,d   Dover, Jeffrey S ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALMOTRIPTAN; BOTULINUM TOXIN A; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CAFFEINE; DICHLORALPHENAZONE; ELETRIPTAN; HYDROCODONE BITARTRATE; IBUPROFEN; ISOMETHEPTENE; MECLOZINE; PARACETAMOL; SUMATRIPTAN SUCCINATE; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; ESTHETIC SURGERY; FACE; FACE SURGERY; FEMALE; HEADACHE; HUMAN; INJECTION; MALE; MEDICAL SPECIALIST; MIGRAINE; PRIORITY JOURNAL; RETINAL MIGRAINE; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; COHORT STUDIES; COSMETIC TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76749145113     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.356     Document Type: Article

References (8)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8): 813-818.
3. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669-676.
4. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache. 2005;45(4):308-314.
5. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain. 2006;125(3):286-295.
6. Blumenfeld AM, Dodick DW, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004; 22(2):167-175.
7. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35-43.
8. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38(2):245-258.